

David E Neal

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5283346/david-e-neal-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

371
papers

24,959
citations

78
h-index

146
g-index

395
ext. papers

28,956
ext. citations

8.3
avg, IF

6.15
L-index

#	Paper	IF	Citations
371	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1415-1424	59.2	1451
370	The evolutionary history of lethal metastatic prostate cancer. <i>Nature</i> , 2015 , 520, 353-357	50.4	857
369	Multiple newly identified loci associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2008 , 40, 316-21	36.3	722
368	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1425-1437	59.2	655
367	CD133, a novel marker for human prostatic epithelial stem cells. <i>Journal of Cell Science</i> , 2004 , 117, 3539-45	4.5	631
366	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. <i>EMBO Journal</i> , 2011 , 30, 2719-33	13	423
365	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013 , 45, 385-91, 391e1-2	36.3	413
364	Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. <i>Prostate</i> , 2004 , 59, 177-89	4.2	410
363	Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. <i>BMJ, The</i> , 2002 , 325, 766-70	5.9	388
362	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. <i>Nature Genetics</i> , 2009 , 41, 1116-21	36.3	360
361	Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. <i>International Journal of Cancer</i> , 2011 , 128, 574-86	7.5	353
360	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018 , 50, 928-936	36.3	340
359	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014 , 46, 1103-9	36.3	331
358	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015 , 47, 736-45	36.3	306
357	The epidermal growth factor receptor and the prognosis of bladder cancer. <i>Cancer</i> , 1990 , 65, 1619-25	6.4	299
356	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. <i>Nature Genetics</i> , 2015 , 47, 367-372	36.3	292
355	Multiple loci with different cancer specificities within the 8q24 gene desert. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 962-6	9.7	283

354	The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. <i>Cancer Cell</i> , 2013 , 23, 35-47	24.3	282
353	Identification and isolation of human prostate epithelial stem cells based on α 1-integrin expression. <i>Journal of Cell Science</i> , 2001 , 114, 3865-3872	5.3	272
352	Multiple loci on 8q24 associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2009 , 41, 1058-60	36.3	252
351	Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014 , 345, 1251343	33.3	250
350	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. <i>Nature Communications</i> , 2015 , 6, 6605	17.4	245
349	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. <i>Nature Genetics</i> , 2011 , 43, 785-91	36.3	243
348	Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. <i>Nature Medicine</i> , 1996 , 2, 912-7	50.5	242
347	Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. <i>Journal of Biological Chemistry</i> , 2002 , 277, 25904-13	5.4	238
346	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. <i>ELife</i> , 2014 , 3,	8.9	229
345	New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. <i>EMBO Reports</i> , 2007 , 8, 871-8	6.5	219
344	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology, The</i> , 2014 , 15, 1521-1532	21.7	218
343	Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. <i>International Journal of Cancer</i> , 2011 , 128, 562-73	7.5	214
342	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011 , 43, 1098-103	36.3	203
341	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , 2011 , 30, 3019-27	13	203
340	Tip60 is a nuclear hormone receptor coactivator. <i>Journal of Biological Chemistry</i> , 1999 , 274, 17599-604	5.4	202
339	Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. <i>Lancet Oncology, The</i> , 2008 , 9, 445-52	21.7	192
338	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 883-895	27.4	184
337	Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. <i>Oncogene</i> , 2003 , 22, 2466-77	9.2	183

336	Structural basis for the nuclear import of the human androgen receptor. <i>Journal of Cell Science</i> , 2008 , 121, 957-68	5.3	164
335	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. <i>BMJ, The</i> , 2012 , 344, d7894	5.9	163
334	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1109-18	21.7	157
333	Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. <i>Molecular Cancer</i> , 2010 , 9, 59	42.1	154
332	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. <i>Nature Genetics</i> , 2012 , 44, 1326-9	36.3	151
331	Screening for prostate cancer. <i>Lancet, The</i> , 2003 , 361, 1122-8	40	145
330	Genome-wide association study identifies new prostate cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2011 , 20, 3867-75	5.6	143
329	Original Articles: Bladder Cancer: Long-Term Outcome Related to Epidermal Growth Factor Receptor Status in Bladder Cancer. <i>Journal of Urology</i> , 1995 , 153, 919-925	2.5	137
328	Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. <i>Biochemical Journal</i> , 2010 , 428, 439-50	3.8	135
327	Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2052-61	4	134
326	Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. <i>Nucleic Acids Research</i> , 2005 , 33, 13-26	20.1	133
325	RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. <i>Neoplasia</i> , 2012 , 14, 476-86	6.4	128
324	It's not just what you say, it's also how you say it: opening the black box of informed consent appointments in randomised controlled trials. <i>Social Science and Medicine</i> , 2009 , 68, 2018-28	5.1	127
323	Genetic correction of PSA values using sequence variants associated with PSA levels. <i>Science Translational Medicine</i> , 2010 , 2, 62ra92	17.5	125
322	Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. <i>Molecular Endocrinology</i> , 2000 , 14, 1618-26		125
321	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 29-36	5.7	121
320	FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. <i>Oncogene</i> , 1999 , 18, 2755-61	9.2	121
319	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016 , 53, 800-811	5.8	121

318	Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	116
317	Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1632-42	4	116
316	Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. <i>Prostate</i> , 1998 , 37, 149-60	4.2	116
315	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018 , 50, 682-692	36.3	112
314	Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. <i>British Journal of Cancer</i> , 2003 , 88, 1682-6	8.7	111
313	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , 2013 , 22, 408-15	5.6	109
312	A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. <i>Human Molecular Genetics</i> , 2013 , 22, 5056-64	5.6	107
311	Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. <i>Contemporary Clinical Trials</i> , 2003 , 24, 272-82		106
310	Reducing warm ischaemia time during laparoscopic partial nephrectomy: a prospective comparison of two renal closure techniques. <i>European Urology</i> , 2007 , 52, 1164-9	10.2	105
309	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-67	24.4	104
308	Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. <i>Journal of Pathology</i> , 2002 , 196, 292-9	9.4	102
307	Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. <i>Nature Communications</i> , 2017 , 8, 374	17.4	99
306	Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. <i>Neoplasia</i> , 2011 , 13, 676-84	6.4	97
305	Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. <i>Cancer Research</i> , 2014 , 74, 896-907	10.1	92
304	Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. <i>BJU International</i> , 2016 , 117, E10-9	5.6	90
303	Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. <i>American Journal of Clinical Nutrition</i> , 2015 , 102, 1142-57	7	89
302	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. <i>Human Molecular Genetics</i> , 2013 , 22, 2520-8	5.6	88
301	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ, The</i> , 2018 , 360, j5757	5.9	85

300	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016 , 76, 2288-2300	10.1	85
299	A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. <i>European Urology</i> , 2014 , 66, 450-6	10.2	85
298	Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 1090-8	12.9	82
297	Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 11252-7	11.5	82
296	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012 , 30, 149-55	4	81
295	Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2325-36	4	80
294	Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. <i>Molecular Cancer</i> , 2011 , 10, 65	42.1	79
293	A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. <i>Journal of Pathology</i> , 2015 , 236, 517-30	9.4	77
292	Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. <i>European Urology</i> , 2015 , 67, 993-1005	10.2	75
291	Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. <i>Neoplasia</i> , 2011 , 13, 887-98	6.4	75
290	Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2528-39	4	75
289	Tip60 is a co-activator specific for class I nuclear hormone receptors. <i>Journal of Biological Chemistry</i> , 2001 , 276, 46841-8	5.4	74
288	Exploring treatment preferences facilitated recruitment to randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 1127-36	5.7	73
287	Keratinocyte growth factor expression in hormone insensitive prostate cancer. <i>Oncogene</i> , 1997 , 15, 1115-20	5.20	73
286	Gene regulatory mechanisms underpinning prostate cancer susceptibility. <i>Nature Genetics</i> , 2016 , 48, 387-97	36.3	72
285	Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. <i>Human Genetics</i> , 2011 , 129, 687-94	6.3	72
284	The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010 , 16, 4374-81	12.9	72
283	Regulation of FGF8 expression by the androgen receptor in human prostate cancer. <i>Oncogene</i> , 2002 , 21, 5069-80	9.2	71

282	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. <i>Genetics in Medicine</i> , 2015 , 17, 789-95	8.1	70
281	The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. <i>International Journal of Cancer</i> , 2012 , 131, E179-89	7.5	69
280	Estrogen receptor beta in prostate cancer: friend or foe?. <i>Endocrine-Related Cancer</i> , 2014 , 21, T219-34	5.7	68
279	The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. <i>PLoS ONE</i> , 2010 , 5, e13363	3.7	68
278	Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. <i>Prostate</i> , 1998 , 37, 223-9	4.2	68
277	LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitylation and intrinsic nuclear localization signals. <i>Clinical Cancer Research</i> , 2009 , 15, 3003-13	12.9	67
276	Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4874-84	12.9	66
275	Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. <i>ACS Chemical Biology</i> , 2009 , 4, 503-25	4.9	65
274	Epidermal growth factor receptor and bladder cancer: a review. <i>Urologia Internationalis</i> , 1992 , 48, 365-71	11.9	65
273	A RANDOMIZED TRIAL COMPARING TRANSURETHRAL RESECTION OF THE PROSTATE, LASER THERAPY AND CONSERVATIVE TREATMENT OF MEN WITH SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC ENLARGEMENT: THE CLasP STUDY. <i>Journal of Urology</i> , 2000 , 164, 65-70	2.5	64
272	Transcutaneous Electrical Nerve Stimulation and Temporary S3 Neuromodulation in Idiopathic Detrusor Instability. <i>Journal of Urology</i> , 1996 , 155, 2005-2011	2.5	64
271	Key considerations for the experimental training and evaluation of cancer odour detection dogs: lessons learnt from a double-blind, controlled trial of prostate cancer detection. <i>BMC Urology</i> , 2014 , 14, 22	2.2	63
270	Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. <i>BJU International</i> , 2009 , 104, 1592-8	5.6	63
269	Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). <i>Journal of Clinical Epidemiology</i> , 2003 , 56, 605-9	5.7	62
268	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021 , 53, 65-75	36.3	62
267	Alterations in beta-catenin expression and localization in prostate cancer. <i>Prostate</i> , 2008 , 68, 1196-205	4.2	61
266	Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4235-41	2.2	60
265	Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. <i>British Journal of Cancer</i> , 2010 , 102, 1335-40	8.7	60

264	Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2874-81	4	60
263	Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. <i>Journal of Cell Biology</i> , 2005 , 170, 191-200	7.3	59
262	The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. <i>Cancer Prevention Research</i> , 2011 , 4, 2051-61	3.2	58
261	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018 , 9, 2256	17.4	57
260	Conventional Urodynamics and Ambulatory Monitoring in the Definition and Management of Bladder Outflow Obstruction. <i>Journal of Urology</i> , 1996 , 155, 506-511	2.5	57
259	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , 2015 , 26, 1603-16	2.8	56
258	Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. <i>International Journal of Cancer</i> , 2012 , 131, 1187-96	7.5	55
257	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015 , 24, 5589-602	5.6	54
256	Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). <i>International Journal of Cancer</i> , 2011 , 128, 440-6	7.5	53
255	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015 , 25, 814-24	9.7	52
254	Control of human PIRH2 protein stability: involvement of TIP60 and the proteasome. <i>Journal of Biological Chemistry</i> , 2004 , 279, 11696-704	5.4	51
253	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012 , 30, 181-7	4	50
252	Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. <i>American Journal of Pathology</i> , 2010 , 177, 943-54	5.8	50
251	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , 2020 , 77, 320-330	10.2	50
250	Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. <i>EMBO Journal</i> , 2014 , 33, 1365-82	13	48
249	Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. <i>British Journal of Cancer</i> , 2009 , 100, 1198-204	8.7	48
248	The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. <i>Prostate</i> , 2010 , 70, 333-40	4.2	48
247	The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. <i>European Urology</i> , 2016 , 70, 214-8	10.2	47

246	Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. <i>BJU International</i> , 2007 , 100, 826-9	5.6	47
245	Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. <i>International Journal of Cancer</i> , 2004 , 108, 887-92	7.5	47
244	aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. <i>Journal of Pathology</i> , 1999 , 189, 564-9	9.4	47
243	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1121-9	4	46
242	Surgical margin length and location affect recurrence rates after robotic prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 109.e7-13	2.8	46
241	Evaluating genetic risk for prostate cancer among Japanese and Latinos. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 2048-58	4	46
240	Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. <i>BJU International</i> , 2011 , 108, 1402-8	5.6	46
239	Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. <i>Prostate</i> , 2008 , 68, 661-74	4.2	46
238	Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 213-8	5.6	46
237	Prostate cancer: to screen or not to screen?. <i>Lancet Oncology, The</i> , 2000 , 1, 17-24	21.7	46
236	Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. <i>PLoS ONE</i> , 2010 , 5, e13485	3.7	46
235	HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. <i>EMBO Molecular Medicine</i> , 2014 , 6, 651-61	12	45
234	The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 126-39	5	45
233	NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. <i>Journal of Urology</i> , 2000 , 163, 630-633	2.5	45
232	Blood lipids and prostate cancer: a Mendelian randomization analysis. <i>Cancer Medicine</i> , 2016 , 5, 1125-36	4.8	45
231	A recurrent truncating germline mutation in the BRIP1/FANCD1 gene and susceptibility to prostate cancer. <i>British Journal of Cancer</i> , 2009 , 100, 426-30	8.7	44
230	Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. <i>Cancer Research</i> , 2012 , 72, 503-15	10.1	44
229	Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. <i>BJU International</i> , 2008 , 101, 547-55	5.6	44

228	The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway. <i>Journal of Biological Chemistry</i> , 2003 , 278, 46087-93	5.4	44
227	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015 , 75, 1467-74	7.4	43
226	Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. <i>International Journal of Cancer</i> , 2009 , 125, 1414-23	7.5	43
225	Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. <i>BJU International</i> , 2003 , 91, 331-6; discussion 336	5.6	42
224	Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences. <i>Trials</i> , 2014 , 15, 323	2.8	41
223	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. <i>Cancer Discovery</i> , 2015 , 5, 368-79	24.4	41
222	Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. <i>Journal of Urology</i> , 2006 , 176, 439-49	2.5	40
221	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. <i>BJU International</i> , 2016 , 118, 869-879	5.6	38
220	Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. <i>European Urology</i> , 2008 , 53, 1186-93	10.2	38
219	Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. <i>Oncogene</i> , 2001 , 20, 5359-65	9.2	38
218	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016 , 7, 10979	17.4	37
217	Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey. <i>BMJ, The</i> , 2010 , 340, c1928	5.9	37
216	First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single UK centre: learning curves of two surgeons. <i>BJU International</i> , 2011 , 108, 739-47	5.6	36
215	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , 2007 , 8, 84	4.5	36
214	Circulating Folate and Vitamin B and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. <i>European Urology</i> , 2016 , 70, 941-951	10.2	36
213	Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). <i>International Journal of Cancer</i> , 2011 , 128, 1442-8	7.5	35
212	RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. <i>Prostate</i> , 2007 , 67, 638-44	4.2	35
211	Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. <i>BJU International</i> , 2006 , 98, 777-82	5.6	35

210	Putative involvement of the histone acetyltransferase Tip60 in ribosomal gene transcription. <i>Nucleic Acids Research</i> , 2004 , 32, 1654-65	20.1	35
209	High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. <i>Clinical Cancer Research</i> , 2008 , 14, 2527-34	12.9	32
208	Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. <i>Molecular Cancer Research</i> , 2015 , 13, 620-635	6.6	31
207	Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. <i>British Journal of Cancer</i> , 2016 , 115, 90-4	8.7	31
206	Basic science aspects of prostate cancer. <i>Seminars in Cancer Biology</i> , 1997 , 8, 21-7	12.7	31
205	HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 74734-74746	3.3	31
204	The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. <i>BMC Family Practice</i> , 2014 , 15, 81	2.6	30
203	Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. <i>Cancer Causes and Control</i> , 2012 , 23, 347-54	2.8	30
202	Men with prostate cancer make positive dietary changes following diagnosis and treatment. <i>Cancer Causes and Control</i> , 2013 , 24, 1119-28	2.8	30
201	Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. <i>PLoS Genetics</i> , 2014 , 10, e1004129	6	30
200	A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. <i>Cancer Causes and Control</i> , 2012 , 23, 907-17	2.8	30
199	Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer. <i>American Journal of Pathology</i> , 2002 , 160, 693-700	5.8	30
198	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018 , 9, 4616	17.4	30
197	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , 2016 , 14, 66	11.4	29
196	SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?. <i>Nature Genetics</i> , 2008 , 40,	36.3	29
195	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017 , 72, 22-31	10.2	28
194	Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. <i>Cancer Causes and Control</i> , 2015 , 26, 205-218	2.8	28
193	Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. <i>BMJ Open</i> , 2014 , 4, e004285	3	28

192	Differential C3NET reveals disease networks of direct physical interactions. <i>BMC Bioinformatics</i> , 2011 , 12, 296	3.6	28
191	Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over. <i>Modern Pathology</i> , 2008 , 21, 54-9	9.8	28
190	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. <i>European Urology</i> , 2019 , 76, 329-337	10.2	28
189	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	27
188	Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. <i>Cancer Causes and Control</i> , 2013 , 24, 323-34	2.8	27
187	Adherence to dietary and lifestyle recommendations and prostate cancer risk in the prostate testing for cancer and treatment (ProtecT) trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2066-77	4	27
186	Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study. <i>International Journal of Cancer</i> , 2013 , 132, 2176-85	7.5	27
185	Asporin is a stromally expressed marker associated with prostate cancer progression. <i>British Journal of Cancer</i> , 2017 , 116, 775-784	8.7	26
184	The ETS family member GABP β modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. <i>Nucleic Acids Research</i> , 2014 , 42, 6256-69	20.1	26
183	The molecular pathology of urological malignancies. <i>Journal of Pathology</i> , 1997 , 183, 380-7	9.4	26
182	Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>BJU International</i> , 2008 , 102, 1400-6	5.6	26
181	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017 , 71, 381-388	10.2	25
180	Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 635-43	2.8	25
179	A role for neurotensin in bicalutamide resistant prostate cancer cells. <i>Prostate</i> , 2007 , 67, 190-202	4.2	25
178	Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. <i>Cancer Causes and Control</i> , 2020 , 31, 431-449	2.8	24
177	Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1356-1365	4.1365	24
176	The transcriptional programme of the androgen receptor (AR) in prostate cancer. <i>BJU International</i> , 2014 , 113, 358-66	5.6	24
175	Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections. <i>BJU International</i> , 2011 , 108, 1597-602	5.6	24

174	Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. <i>FEBS Letters</i> , 1997 , 405, 328-32	3.8	24
173	Pro-neural transcription factors as cancer markers. <i>BMC Medical Genomics</i> , 2008 , 1, 17	3.7	24
172	Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. <i>PLoS ONE</i> , 2010 , 5, e10858	3.7	24
171	Response of Degarelix treatment in human prostate cancer monitored by HR-MAS H NMR spectroscopy. <i>Metabolomics</i> , 2016 , 12, 120	4.7	24
170	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. <i>Oncologist</i> , 2016 , 21, 716-22	5.7	24
169	Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2019 , 48, 1416-1424	7.8	24
168	Genome-wide association study of prostate cancer-specific survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1796-800	4	23
167	Design and preliminary recruitment results of the Cluster randomised triAL of PSA testing for Prostate cancer (CAP). <i>British Journal of Cancer</i> , 2014 , 110, 2829-36	8.7	23
166	The role of surgery in high-risk localised prostate cancer. <i>BJU International</i> , 2012 , 109, 648-58	5.6	23
165	Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2014 , 32, 185-91	4	23
164	The relation between adiposity throughout the life course and variation in IGFs and IGFbps: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. <i>Cancer Causes and Control</i> , 2010 , 21, 1829-42	2.8	23
163	Surface localization of sacral foramina for neuromodulation of bladder function. An anatomical study. <i>European Urology</i> , 1996 , 29, 90-8	10.2	23
162	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , 2017 , 140, 75-85	7.5	22
161	Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla. <i>Magnetic Resonance in Medicine</i> , 2011 , 65, 914-9	4.4	22
160	Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer. <i>Biochemistry</i> , 2013 , 52, 1429-36	3.2	21
159	Is continent diversion using the Mitrofanoff principle a viable long-term option for adults requiring bladder replacement?. <i>BJU International</i> , 2008 , 102, 236-40	5.6	21
158	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. <i>Cancer Prevention Research</i> , 2018 , 11, 687-696	3.2	21
157	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. <i>PLoS Genetics</i> , 2017 , 13, e1007001	6	20

156	Identification of potential therapeutic targets in prostate cancer through a cross-species approach. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	20
155	Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature. <i>BJU International</i> , 2015 , 115, 698-704	5.6	20
154	Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy. <i>European Urology</i> , 2012 , 62, 649-55	10.2	20
153	Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. <i>Cancer Causes and Control</i> , 2012 , 23, 575-88	2.8	20
152	Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. <i>British Journal of Cancer</i> , 2011 , 104, 875-81	8.7	20
151	Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2833-8	4	20
150	Identification of new genetic risk factors for prostate cancer. <i>Asian Journal of Andrology</i> , 2009 , 11, 49-55	2.8	20
149	Mucus production after transposition of intestinal segments into the urinary tract. <i>World Journal of Urology</i> , 2004 , 22, 178-85	4	20
148	Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. <i>Oncotarget</i> , 2015 , 6, 21675-84	3.3	20
147	Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). <i>BMJ Open</i> , 2016 , 6, e011063	3	20
146	Late Imaging with [1-(11)C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1144-9	8.9	19
145	Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: opportunities for lifestyle modification. <i>International Journal of Cancer</i> , 2015 , 137, 1509-15	7.5	19
144	Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. <i>Cancer Causes and Control</i> , 2012 , 23, 1865-73	2.8	19
143	Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin d and prostate cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 597-606	4	19
142	Mutation analysis of the MSMB gene in familial prostate cancer. <i>British Journal of Cancer</i> , 2010 , 102, 4148-7	4.7	19
141	Screening for prostate cancer remains controversial. <i>Lancet, The</i> , 2009 , 374, 1482-3	40	19
140	A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). <i>Contemporary Clinical Trials</i> , 2006 , 27, 413-9	2.3	19
139	High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens?. <i>Carcinogenesis</i> , 1996 , 17, 601-4	4.6	19

138	DESNT: A Poor Prognosis Category of Human Prostate Cancer. <i>European Urology Focus</i> , 2018 , 4, 842-850	5.1	18
137	Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer. <i>Human Molecular Genetics</i> , 2016 , 25, 1008-18	5.6	18
136	Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 163-5	4	18
135	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. <i>International Journal of Cancer</i> , 2016 , 139, 1520-33	7.5	18
134	Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e110569	3.7	17
133	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 628-36	5.7	17
132	Labeling and identification of LNCaP cell surface proteins: a pilot study. <i>Prostate</i> , 2007 , 67, 943-54	4.2	17
131	Ryanodine receptors in human bladder smooth muscle. <i>Experimental Physiology</i> , 1999 , 84, 41-6	2.4	17
130	A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. <i>Oncotarget</i> , 2016 , 7, 21393-403	3.3	17
129	A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. <i>Cancer Research</i> , 2019 , 79, 274-285	10.1	17
128	Detailed analysis of operating time learning curves in robotic prostatectomy by a novice surgeon. <i>BJU International</i> , 2012 , 109, 1074-80	5.6	16
127	Method for sampling tissue for research which preserves pathological data in radical prostatectomy. <i>Prostate</i> , 2013 , 73, 194-202	4.2	16
126	Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. <i>European Urology</i> , 2008 , 53, 777-84	10.2	16
125	Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group. <i>Journal of Medical Ethics</i> , 2008 , 34, 37-40	2.5	16
124	Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. <i>BMJ, The</i> , 2007 , 335, 1139	5.9	16
123	Establishing a robotic prostatectomy programme: The impact of mentoring using a structured approach. <i>BJU International</i> , 2006 , 97, 1143-4	5.6	16
122	Vitamin B12 malabsorption following bladder reconstruction or diversion with bowel segments. <i>ANZ Journal of Surgery</i> , 2002 , 72, 479-82	1	16
121	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. <i>BMJ Open</i> , 2017 , 7, e017729	3	16

120	No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses. <i>PLoS ONE</i> , 2012 , 7, e34221	3.7	16
119	Validation of the Hospital Episode Statistics Outpatient Dataset in England. <i>Pharmacoeconomics</i> , 2016 , 34, 161-8	4.4	15
118	Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. <i>BMJ Open</i> , 2015 , 5, e008953	3	15
117	The role of 1.5 Tesla magnetic resonance imaging in staging prostate cancer. <i>ANZ Journal of Surgery</i> , 2013 , 83, 234-8	1	15
116	PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2009 , 12, 296-300	6.2	15
115	Stage shift in PSA-detected prostate cancers - effect modification by Gleason score. <i>Journal of Medical Screening</i> , 2009 , 16, 98-101	1.4	15
114	Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. <i>British Journal of Cancer</i> , 2009 , 101, 390-4	8.7	15
113	Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?. <i>European Journal of Cancer</i> , 2009 , 45, 2569-73	7.5	15
112	Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. <i>British Journal of Cancer</i> , 2011 , 105, 931-7	8.7	15
111	Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1877-85	4	15
110	Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. <i>Urology</i> , 1997 , 50, 55-61	1.6	15
109	Adhesion of lymphocytes to bladder cancer cells: the role of the alpha(E)beta(7) integrin. <i>Cancer Immunology, Immunotherapy</i> , 2002 , 51, 483-91	7.4	15
108	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. <i>European Urology</i> , 2017 , 72, 509-518	10.2	14
107	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1731-1738	4	14
106	Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?. <i>Cancer Causes and Control</i> , 2016 , 27, 1465-1474	2.8	14
105	Misclassification of outcome in case-control studies: Methods for sensitivity analysis. <i>Statistical Methods in Medical Research</i> , 2016 , 25, 2377-2393	2.3	14
104	Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. <i>Oncotarget</i> , 2014 , 5, 3785-99	3.3	14
103	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , 2020 , 125, 506-514	5.6	14

102	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021 , 12, 1236	17.4	14
101	Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer. <i>International Journal of Cancer</i> , 2017 , 140, 1881-1887	7.5	13
100	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. <i>British Journal of Cancer</i> , 2016 , 114, 945-52	8.7	13
99	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. <i>International Journal of Cancer</i> , 2017 , 140, 322-328	7.5	13
98	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. <i>Journal of Urology</i> , 2017 , 197, 607-613	2.5	13
97	MenQ knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. <i>BMC Cancer</i> , 2014 , 14, 812	4.8	13
96	PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression. <i>International Journal of Cancer</i> , 2011 , 128, 1462-70	7.5	13
95	Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. <i>Journal of Health Services Research and Policy</i> , 2009 , 14, 77-81	2.4	13
94	Transurethral Prostate Resection, Noncontact Laser Therapy or Conservative Management in Men With Symptoms of Benign Prostatic Enlargement? An Economic Evaluation. <i>Journal of Urology</i> , 2002 , 168, 2476-2482	2.5	13
93	Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). <i>European Journal of Oncology Nursing</i> , 2018 , 32, 73-81	2.8	12
92	Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. <i>European Urology</i> , 2010 , 57, 446-52	10.2	12
91	Detrusor contraction strength in men undergoing prostatectomy. <i>Neurourology and Urodynamics</i> , 1993 , 12, 109-121	2.3	12
90	Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre. <i>BJU International</i> , 2016 , 118, 779-784	5.6	12
89	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. <i>Oncogene</i> , 2019 , 38, 1136-1150	9.2	12
88	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , 2021 , 4, 570-579	6.7	12
87	Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel. <i>Endocrine-Related Cancer</i> , 2016 , 23, 797-812	5.7	11
86	Androgen deprivation treatment in prostate cancer. <i>BMJ, The</i> , 2013 , 346, e8555	5.9	11
85	Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 67-73	5.7	11

84	AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. <i>Cell Cycle</i> , 2008 , 7, 3525-33	4.7	11
83	Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. <i>PLoS ONE</i> , 2011 , 6, e26527	3.7	11
82	A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010 , 1, 175-83	0.9	11
81	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. <i>BMC Health Services Research</i> , 2015 , 15, 80	2.9	10
80	Very low PSA concentrations and deletions of the KLK3 gene. <i>Clinical Chemistry</i> , 2013 , 59, 234-44	5.5	10
79	Selective Targeting of the TPX2 Site of Importin- β Using Fragment-Based Ligand Design. <i>ChemMedChem</i> , 2015 , 10, 1232-9	3.7	10
78	Global assessment of network inference algorithms based on available literature of gene/protein interactions. <i>Turkish Journal of Biology</i> , 2013 , 37, 547-555	3.1	10
77	PSA testing for prostate cancer improves survival--but can we do better?. <i>Lancet Oncology</i> , 2010 , 11, 702-3	21.7	10
76	Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?. <i>BJU International</i> , 2008 , 102, 1629-33	5.6	10
75	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019 , 145, 3244-3256	7.5	9
74	Gleason drift in the NIHR ProtecT study. <i>Histopathology</i> , 2015 , 66, 438-46	7.3	9
73	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. <i>Cancer Causes and Control</i> , 2018 , 29, 383-388	2.8	9
72	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018 , 96, 35-46	5.7	9
71	RAS pathways in prostate cancer - mediators of hormone resistance?. <i>Current Cancer Drug Targets</i> , 2010 , 10, 834-9	2.8	9
70	Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>European Journal of Cancer</i> , 2009 , 45, 3254-61	7.5	9
69	The immunohistochemical detection of cripto-1 in benign and malignant human bladder. <i>Journal of Pathology</i> , 1998 , 185, 108-11	9.4	9
68	Fournier's gangrene. <i>Nature Reviews Urology</i> , 2006 , 3, 54-7; quiz 58		9
67	Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. <i>Urology</i> , 2004 , 64, 317-22	1.6	9

66	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011 , 2, 316-27	0.9	9
65	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020 , 24, 1-176	4.4	9
64	Neuromodulation in bladder dysfunction. <i>Current Opinion in Obstetrics and Gynecology</i> , 1998 , 10, 395-9	2.4	9
63	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 208-216	4	9
62	HES5 silencing is an early and recurrent change in prostate tumourigenesis. <i>Endocrine-Related Cancer</i> , 2015 , 22, 131-44	5.7	8
61	Independence of HIF1a and androgen signaling pathways in prostate cancer. <i>BMC Cancer</i> , 2020 , 20, 469	4.8	8
60	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. <i>Journal of Urology</i> , 2018 , 199, 1470-1474	2.5	8
59	Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. <i>Cancer Causes and Control</i> , 2013 , 24, 39-45	2.8	8
58	PROSPECTIV-a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2014 , 4, e005186 ³		8
57	Enhanced recovery: from principles to practice in urology. <i>BJU International</i> , 2010 , 105, 1199-201	5.6	8
56	Effects of a new 5 alpha reductase inhibitor (epristeride) on human prostate cell cultures. <i>Prostate</i> , 1997 , 32, 259-65	4.2	8
55	Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial Lessons learnt from CAP (Cluster randomised triAL of PSA testing for Prostate cancer). <i>BMC Medical Research Methodology</i> , 2015 , 15, 6	4.7	7
54	General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. <i>BJU International</i> , 2012 , 110, 24-7	5.6	7
53	Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. <i>BJU International</i> , 2013 , 111, 1148-55	5.6	7
52	Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. <i>European Journal of Cancer Prevention</i> , 2013 , 22, 121-5	2	7
51	The outcome of prostatectomy on chronic retention of urine. <i>Journal of Urology</i> , 1991 , 146, 1029-33	2.5	7
50	Trends in the use of radiotherapy and radical surgery for patients with bladder urothelial cell carcinoma in East Anglia, 1995-2006. <i>BJU International</i> , 2011 , 108, 1106-14	5.6	6
49	Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. <i>BJU International</i> , 2011 , 108, 1409-14	5.6	6

48	Psychological distress and prostate specific antigen levels in men with and without prostate cancer. <i>Brain, Behavior, and Immunity</i> , 2009 , 23, 1073-8	16.6	6
47	Screening for prostate cancer. <i>Annals of Oncology</i> , 1998 , 9, 1289-92	10.3	6
46	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , 2020 , 28, 1467-1475	5.3	5
45	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. <i>Statistical Methods in Medical Research</i> , 2016 , 25, 1875-1891	2.3	5
44	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. <i>British Journal of Cancer</i> , 2017 , 117, 734-743	8.7	5
43	Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. <i>PLoS ONE</i> , 2015 , 10, e0136735	3.7	5
42	Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts. <i>BJU International</i> , 2016 , 118, 911-918	5.6	5
41	The Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , 2020 , 12,	6.6	4
40	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <i>Cancer Epidemiology</i> , 2018 , 52, 99-105	2.8	4
39	Regulation of the localisation and function of the oncogene LYRIC/AEG-1 by ubiquitination at K486 and K491. <i>Molecular Oncology</i> , 2014 , 8, 633-41	7.9	4
38	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. <i>Cancer Epidemiology</i> , 2011 , 35, 139-44	2.8	4
37	Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumour. <i>BJU International</i> , 2008 , 101, 570-4	5.6	4
36	Can we accurately identify men with low risk prostate cancer?. <i>Journal of Urology</i> , 2008 , 180, 1217-8	2.5	4
35	Missing channels in two-colour microarray experiments: combining single-channel and two-channel data. <i>BMC Bioinformatics</i> , 2007 , 8, 26	3.6	4
34	The morbidity of transurethral resection of the prostate. <i>Current Opinion in Urology</i> , 1996 , 6, 147-150	2.8	4
33	Transrectal ultrasound guided needle electromyography of the urethral sphincter in males. <i>Neurourology and Urodynamics</i> , 1995 , 14, 359-63	2.3	4
32	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1063-1070	8.7	4
31	Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial. <i>European Journal of Cancer Prevention</i> , 2019 , 28, 569-575	2	4

30	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. <i>Trials</i> , 2016 , 17, 497	2.8	3
29	Predictors of the use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: data from a pilot study of 1756 cases 2004-2011. <i>BJU International</i> , 2013 , 111, 1061-7	5.6	3
28	A model of the natural history of screen-detected prostate cancer. <i>British Journal of Cancer</i> , 2006 , 95, 1122-3	8.7	3
27	Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study. <i>Health Services and Delivery Research</i> , 2015 , 3, 1-138	1.5	3
26	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. <i>Scientific Reports</i> , 2021 , 11, 9264	4.9	3
25	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 532-541	6.2	3
24	MenQ experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. <i>Cancer Causes and Control</i> , 2021 , 32, 261-269	2.8	3
23	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , 2019 , 113, 200-213	5.7	2
22	Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial. <i>Cancer Causes and Control</i> , 2017 , 28, 877-888	2.8	2
21	The first national clinical audit of prostate cancer care. <i>BJU International</i> , 2013 , 112, 883-4	5.6	2
20	Where are we now with prostate cancer diagnosis?. <i>Trends in Urology & Men's Health</i> , 2010 , 1, 18-20	0.3	2
19	Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1140262	1.2	2
18	Prostate Cancer UK: the Blue Skies Forum. <i>Trends in Urology & Men's Health</i> , 2013 , 4, 39-43	0.3	1
17	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , 2012 , 31, 1617-1617	13	1
16	Including a no active intervention arm in surgical trials is possible: evidence from the CLasP randomised trial. <i>Journal of Health Services Research and Policy</i> , 2003 , 8, 209-14	2.4	1
15	Evaluation of dendritic cell immunogenicity after activation and chemical fixation: a mixed lymphocyte reaction model. <i>Journal of Immunotherapy</i> , 2002 , 25, 152-61	5	1
14	Systematic Review and Meta-Analysis of the Associations Between Body Mass Index, Prostate Cancer, Advanced Prostate Cancer and Prostate Specific Antigen		1
13	A genetic risk score to guide age-specific, personalized prostate cancer screening		1

12	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations		1
11	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , 2020 , 10, e036024	3	1
10	A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. <i>World Journal of Urology</i> , 2021 , 1	4	1
9	Role of the androgen receptor in prostate cancer. <i>Trends in Urology & Mens Health</i> , 2013 , 4, 26-30	0.3	
8	Growing Teratoma Syndrome: A Case of Mistaken Identity. <i>British Journal of Medical and Surgical Urology</i> , 2011 , 4, 272-275		
7	Treatment for PSA screen-detected prostate cancer: what are the options?. <i>Nature Reviews Urology</i> , 2009 , 6, 132-4	5.5	
6	Fibroblast Growth Factor Receptor (FGFR). <i>Expert Opinion on Therapeutic Targets</i> , 1997 , 1, 173-175		
5	The role of the Postgraduate Medical Education and Training Board (PMETB). <i>Surgery</i> , 2008 , 26, 403-407	0.3	
4	Clean intermittent self catheterization. <i>International Urogynecology Journal</i> , 1993 , 4, 250-251	2	
3	Non-invasive diagnosis 2007 , 39-49		
2	Pre-malignant Disease in the Prostate 2011 , 467-491		
1	The Development of a Robotic Urology Program in the UK 2011 , 97-109		